Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NEUP with free AI briefings, catalyst countdowns, and dilution alerts.

NEUP · Neuphoria Therapeutics Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$19.9M Cash on Hand
56.2mo Cash Runway
Follow NEUP by email Get an email when NEUP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NEUP, unsubscribe in one click. Privacy

📣 What NEUP Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

NEUP holds $19.9M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.1M/quarter from operations, an estimated runway of 56.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NEUP files for a raise →

👥 Who Owns NEUP

Insiders 100% Institutions (20 holders) 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
Spyros Papapetropoulos
President and CEO, Director · +113,617 options
Insider 5,999,940 110.88% 2024-07-01
Lynx1 Capital Management LP
10% owner
Insider 875,328 16.18% 2025-12-26
AdvisorShares Trust Institution (13G, 5%+) 312,895 5.78% 2026-09-30
Peter Miles Winston Davies
Director · +15,320 options
Insider 269,984 4.99% 2024-07-01
David Ian Wilson
Director · +15,412 options
Insider 251,939 4.66% 2024-07-01
Alan Fisher
Director · +30,731 options
Insider 100,000 1.85% 2024-07-01

Share count 5,411,334 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full NEUP picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NEUP and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.